Company intelligence / Profile preview

Tube Pharmaceuticals

Austria

Ownership: Private
Development stage: Other

Overview

Tube Pharmaceuticals developed cytolysin-based small-molecule cytotoxic payloads used in antibody-drug conjugates; these payloads have reached first-in-human clinical evaluation in partner programs such as OMTX705, an ADC targeting cancer-associated fibroblasts in metastatic solid tumors, but Tube’s own assets were primarily pre-clinical when the company was acquired.[1][2]

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

OncomatryxPolyTherics

Beyond the preview

Go deeper on Tube Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tube Pharmaceuticals.

Explore the full profile